Fatty acid synthase (FASN), an enzyme that drives de novo lipogenesis, plays a relevant role in metabolic disorders such as obesity, non-alcoholic fatty liver disease (NAFLD) or type 2 diabetes.
The Cyprus Association of Liver Patients “Promitheas” launched a new information campaign on Friday, focusing on the risks and prevention of fatty liver disease. According to the association, ...